Nektar Therapeutics (NKTR): Share Price, Stock Analysis, Annual Report | Value Research Get Nektar Therapeutics (NKTR)'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house.
info-circle
company-logo

Click to see a quick summary and important updates about this stock!Dismiss

  • Healthcare
  • Biotechnology & Pharma Research

Nektar Therapeutics (NKTR)

NASDAQ: NKTR

  • Market Capitalisation info

    $963 Mln


  • 12 Month Earnings info

    $-491 Mln

  • Price to Earnings info

    --

$5.14

As on 12-Aug-2022 16:00 EDT

up-down-arrow $0.193.84%

  • Prev Close info

    $4.95

  • Day's Openinfo

    $4.94

  • Today's Highinfo

    $5.15

  • Today's Lowinfo

    $4.94

  • Today's Volumeinfo

    1,675,564

Please wait...

Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Nektar Therapeutics (NKTR)
-61.95 45.61 43.18 -64.18 -37.37 -22.39 -4.61
S&P BSE Sensex
2.08 9.32 9.94 9.05 16.53 13.76 12.97
S&P Small-Cap 600
-8.13 14.13 12.23 -5.78 11.43 9.16 11.05
As on 12-Aug-2022
2021
2020
2019
2018
2017
2016
2015
Nektar Therapeutics (NKTR)
-20.53 -21.24 -34.33 -44.78 386.72 -27.18 8.71
S&P Small-Cap 600
25.27 9.57 20.86 -9.70 11.73 24.74 -3.36
S&P BSE Sensex
21.99 15.75 14.38 5.87 27.91 1.95 -5.03

Valuation

Stock
Peer Median

Growth & Efficiency

Stock
Peer Median

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other Details

        CEO, Pres & Director

        Mr. Howard W. Robin

        Sr. VP, Gen. Counsel & Sec.

        Mr. Mark A. Wilson

        Headquarters

        San Francisco, CA
        Edit edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap info

          $963.26 Mln

        • Revenue (TTM) info

          $103.08 Mln

        • Earnings (TTM) info

          $-491.26 Mln

        • Cash info

          $667.03 Mln

        • Total Debt info

          $142.24 Mln

        • Insider's Holding

          1.09%

        • Liquidity info

          Low

        • 52 Week range info

          $3.02 - 19.37

        • Shares outstanding info

          186,274,000

        • 10 Years Aggregate:

          CFO: $-917.22 Mln

          EBITDA: $-893.92 Mln

          Net Profit: $-1,446.81 Mln

        About The Company

        • Business

          Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally.

        • IPO Date

          03-May-1994

        • CEO, Pres & Director

          Mr. Howard W. Robin

        • Sr. VP, Gen. Counsel & Sec.

          Mr. Mark A. Wilson

        • Listing info

          NASDAQ: NKTR

        • Country

          United States

        • Headquarters info

          San Francisco, CA

        • Website info

          https://www.nektar.com